Bausch + Lomb has announced that it has bought some of the assets and intellectual property of Miochol, a drug used during eye surgery to constrict the pupil. Affiliates of Novartis sold the assets, and will provide technical assistance to B+L during the transition period. B+L has the assets for the U.S., Canada, Australia, Korea and other markets outside the European Economic Area, and plans to buy the rest of the assets after regulators have OK'ed the purchase.